These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1804700)

  • 1. [The genetically determined polymorphism of metabolic oxidation of the sparteine-debrisoquin type].
    Piotrovskiĭ VK; Belolipetskaia VG
    Farmakol Toksikol; 1991; 54(6):60-6. PubMed ID: 1804700
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical aspects of the polymorphism of oxidation phenotype].
    Mrozikiewicz PM
    Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):608-10. PubMed ID: 1488339
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between imipramine metabolism and the sparteine oxidation polymorphism.
    Brøsen K
    Dan Med Bull; 1988 Oct; 35(5):460-8. PubMed ID: 3066590
    [No Abstract]   [Full Text] [Related]  

  • 4. Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.
    Walter-Sack I; Eichelbaum M; de Vries JX; Weber E
    Klin Wochenschr; 1988 Nov; 66(21):1097-8. PubMed ID: 3236759
    [No Abstract]   [Full Text] [Related]  

  • 5. [The polymorphism of pachycarpine oxidation].
    Piotrovskiĭ VK; Belolipetskaia VG; Rumiantsev DO; Metelitsa VI
    Eksp Klin Farmakol; 1992; 55(4):56-8. PubMed ID: 1458193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
    Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 9. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of cytochrome P450 gene superfamily for the clinical pharmacokinetics of drugs].
    Brøsen K
    Ugeskr Laeger; 1991 Feb; 153(6):417-22. PubMed ID: 2000644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility.
    Gonzalez FJ
    Birth Defects Orig Artic Ser; 1990; 26(1):17-42. PubMed ID: 2224077
    [No Abstract]   [Full Text] [Related]  

  • 12. Polymerase chain reaction and its potential as a pharmacokinetic tool.
    Heim MH
    Clin Pharmacokinet; 1992 Nov; 23(5):321-7. PubMed ID: 1362142
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type.
    Adams M; Lennard MS; Otton SV; Tucker GT; Woods HF
    Biochem Pharmacol; 1991 Jul; 42(4):947-9. PubMed ID: 1867648
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic polymorphism of drug metabolism.
    Paxton JW
    N Z Med J; 1984 Aug; 97(762):567-9. PubMed ID: 6591031
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetically determined sparteine oxidation polymorphism in a Polish population.
    Orzechowska-Juzwenko K; Pawlik J; Niewiński P; Milejski P; Dembowski J; Turek J; Goździk A; Swiebodzki L; Hora Z
    Eur J Clin Pharmacol; 1994; 46(5):481-3. PubMed ID: 7957549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.